Ocular Therapeutix (OCUL) Depreciation & Amortization (CF) (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Depreciation & Amortization (CF) of $1.9 million for Q2 2026, up 80.23% year-over-year from $1.0 million in Q2 2025, and up 44.27% on a QoQ basis from $1.3 million in Q1 2026.
Ocular Therapeutix (OCUL) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Depreciation & Amortization (CF) for 14 years, with the latest figure at $1.9 million in Q2 2026.
- Depreciation & Amortization (CF) for Q2 2026 came in at $1.9 million, up 80.23% year-over-year; the trailing twelve-month figure through Jun 2026 was $5.5 million (up 39.21% YoY), and the FY2025 annual result was $4.3 million, up 14.18% from the prior year.
- Depreciation & Amortization (CF) advanced to $1.9 million in Q2 2026, from $1.3 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $1.9 million in Q2 2026 and troughed at $483000.0 in Q1 2023.
- A 5-year average of $907666.7 and a median of $953500.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The widest annual swing landed in 2022, when Depreciation & Amortization (CF) retreated 14.31%; it then surged 95.11% in 2023.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $491000.0 in 2022, then soared by 95.11% to $958000.0 in 2023, then decreased by 0.73% to $951000.0 in 2024, then jumped by 31.13% to $1.2 million in 2025, then soared by 48.44% to $1.9 million in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $1.9 million in Q2 2026, $1.3 million in Q1 2026, and $1.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 1.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.85 Mn |
| Jun 30, 2026 | 1.85 Mn |
| Mar 31, 2026 | 1.28 Mn |
| Mar 31, 2026 | 1.28 Mn |
| Dec 31, 2025 | 1.25 Mn |
| Dec 31, 2025 | 1.25 Mn |
| Sep 30, 2025 | 1.07 Mn |
| Sep 30, 2025 | 1.07 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | 981,000.00 |
| Mar 31, 2025 | 981,000.00 |
| Dec 31, 2024 | 951,000.00 |
| Dec 31, 2024 | 951,000.00 |
| Sep 30, 2024 | 958,000.00 |
| Sep 30, 2024 | 958,000.00 |
| Jun 30, 2024 | 956,000.00 |
| Jun 30, 2024 | 956,000.00 |
| Mar 31, 2024 | 920,000.00 |
| Mar 31, 2024 | 920,000.00 |